Kornelia Polyak

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 30(Granted Patents)

Company Filing History:

9 out of 1,209

Dana-farber-cancer Institute Inc.

patents

3 out of 3,687

Johns Hopkins University

patents

1 out of 2,893

The General Hospital Corporation

patents

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11666580 - Mechanism of resistance to bet bromodomain inhibitors (2023-06-06),

2. 11644466 - Methods for treating, preventing and predicting risk of developing breast cancer (2023-05-09),

3. 9556430 - Gene methylation and expression (2017-01-31),

4. 8110370 - IBC-1 (Invasive Breast Cancer-1), a putative oncogene amplified in breast cancer (2012-02-07),

5. 8034561 - HIN-1, a tumor suppressor gene (2011-10-11),

6. 7776541 - Psoriasin expression by breast epithelial cells (2010-08-17),

7. 7625715 - HIN-1, a tumor suppressor gene (2009-12-01),

8. 7608696 - IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer (2009-10-27),

9. 7465553 - Psoriasin expression by breast epithelial cells (2008-12-16),

10. 6815166 - HIN-1, a tumor suppressor gene (2004-11-09),

11. 6750021 - Subtle mitochondrial mutations as tumor markers (2004-06-15),

12. 6432640 - P53-induced apoptosis (2002-08-13),

13. 6344322 - Subtle mitochondrial mutations as tumor markers (2002-02-05),

Title: The Innovative Contributions of Kornelia Polyak in Cancer Research

Introduction

Kornelia Polyak, an esteemed inventor and researcher located in Brookline, MA, has made significant strides in the realm of cancer research. With an impressive portfolio of 13 patents to her name, her innovations focus on enhancing therapies for cancer treatment. Her work not only contributes to scientific understanding but also has the potential to transform clinical practices.

Latest Patents

Polyak's most recent patents include a groundbreaking mechanism for overcoming resistance to bromodomain inhibitors. This innovation presents a combination therapy that features a BET inhibitor alongside various other agents, such as protein phosphatase 2A (PP2A) activators and B-cell lymphoma inhibitors. This synergistic approach aims to enhance treatment efficacy for patients who may not respond to traditional monotherapies. Additionally, she has developed methods for identifying individuals at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy, as well as methods for treating and predicting breast cancer risk. These advancements highlight her commitment to improving cancer treatment outcomes.

Career Highlights

Throughout her career, Kornelia Polyak has associated with prestigious institutions. She has notably worked at the Dana-Farber Cancer Institute and The Johns Hopkins University. Her contributions to the field of cancer research are pivotal, facilitating a deeper understanding of cancer biology and the development of innovative therapies.

Collaborations

Polyak has collaborated with a range of esteemed colleagues, including Bert Vogelstein, further enriching her research endeavors. These collaborations play a crucial role in fostering advancements in the understanding of cancer mechanisms and treatment strategies.

Conclusion

Kornelia Polyak’s contributions to cancer research through her numerous patents and collaborations exemplify her dedication to finding innovative solutions for challenging medical issues. As research continues to evolve, her work will undoubtedly inspire future innovations in the oncology field.

This text is generated by artificial intelligence and may not be accurate.